AM-Pharma opts for adaptive design route after successful phase I
By Nuala Moran
Tuesday, March 25, 2014
LONDON – AM-Pharma has cleared the way to getting its alkaline phosphatase product back into patient trials after reporting positive results in a phase I study in 50 healthy volunteers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.